Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.
Giaquinto
C
C
Department of Pediatrics, University of Padova, Padua, Italy.
De Romeo
A
A
Giacomet
V
V
Rampon
O
O
Ruga
E
E
Burlina
A
A
De Rossi
A
A
Sturkenboom
M
M
D'Elia
R
R
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019344:Lactic Acid / Q000097:blood*; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D018743:Perinatal Care; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011295:Prenatal Care; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D018119:Stavudine / Q000009:adverse effects / Q000627:therapeutic use; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D019344:Lactic Acid; D015215:Zidovudine; D018119:Stavudine